GenomicsPharmacogenomics

Pharmacogenomics Explained: How Your DNA Affects Drugs

Learn how genetic variants in CYP enzymes affect drug metabolism. A beginner's guide to pharmacogenomics with real examples.

Ryan Bethencourt
April 9, 2026
10 min read

Why the Same Drug Works Differently for Different People

You have probably noticed that a medication that works perfectly for one person can be ineffective or cause side effects in another. The reason often lies in your DNA. Genetic variants in enzymes that metabolize drugs can speed up or slow down how your body processes a medication, changing its concentration in your bloodstream and its therapeutic effect.

Pharmacogenomics (PGx) is the field that studies these gene-drug interactions. It aims to move medicine away from trial-and-error prescribing toward dosing guided by your genotype. Over 300 FDA-approved drug labels now include pharmacogenomic information, and major health systems are beginning to integrate PGx testing into routine clinical workflows.

The CYP Enzyme Family: Your Drug Metabolism Machinery

The cytochrome P450 (CYP) superfamily is the most important group of drug-metabolizing enzymes. These proteins, primarily expressed in the liver, chemically modify drugs so they can be excreted. Four CYP enzymes handle the majority of drug metabolism:

  • CYP2D6 — Metabolizes roughly 25% of all prescribed drugs, including codeine, tamoxifen, many SSRIs, and ondansetron. Highly polymorphic with over 100 known alleles.
  • CYP2C19 — Key enzyme for clopidogrel (Plavix), proton pump inhibitors, and several antidepressants. Poor metabolizers have significantly reduced clopidogrel activation.
  • CYP2C9 — Metabolizes warfarin, phenytoin, and many NSAIDs. Variants in CYP2C9 are a major factor in warfarin dose requirements.
  • CYP3A4 — The workhorse enzyme that processes approximately 50% of all medications, including statins, immunosuppressants, and many cancer drugs.

Metabolizer Phenotypes Explained

Your genotype for each CYP gene determines your metabolizer phenotype — a clinical classification that predicts how fast you process drugs through that enzyme:

  • Poor Metabolizer (PM) — Little to no functional enzyme. Drugs metabolized by this enzyme accumulate to higher levels, increasing side effect risk. Prodrugs that require activation (like codeine to morphine) may not work at all.
  • Intermediate Metabolizer (IM) — Reduced enzyme activity. May need dose adjustments for some drugs.
  • Normal Metabolizer (NM) — Typical enzyme activity. Standard drug dosing is usually appropriate.
  • Rapid/Ultra-rapid Metabolizer (RM/UM) — Increased enzyme activity. Drugs are cleared faster, potentially reducing efficacy. For prodrugs, conversion is faster, which can cause toxicity (e.g., codeine to morphine in CYP2D6 ultra-rapid metabolizers).

Real-World Examples

Warfarin and CYP2C9 + VKORC1

Warfarin is the classic pharmacogenomics case. Variants in CYP2C9 slow warfarin metabolism, and variants in VKORC1 (the drug target) alter sensitivity. Together, genetics explains roughly 40% of the variability in warfarin dose requirements. The FDA label recommends considering genotype when initiating therapy.

Codeine and CYP2D6

Codeine is a prodrug that requires CYP2D6 to convert it into morphine. Poor metabolizers get almost no pain relief. Ultra-rapid metabolizers convert codeine to morphine too quickly, risking respiratory depression — this is why codeine carries an FDA black box warning for pediatric use.

Clopidogrel and CYP2C19

Clopidogrel (Plavix) requires CYP2C19 activation. Approximately 2–15% of people (depending on ethnicity) are CYP2C19 poor metabolizers and get inadequate platelet inhibition, increasing their risk of cardiovascular events after stent placement.

Warning
This information is educational and does not constitute medical advice. Never change your medications based on genetic results without consulting your doctor or pharmacist. Always discuss pharmacogenomic findings with a qualified healthcare provider.

How to Check Your Pharmacogenomics Profile

If you have 23andMe or AncestryDNA raw data, you can look up key pharmacogenomic SNPs using our free Pharmacogenomics Checker. Select a gene, enter your genotype, and get an explanation of your predicted metabolizer status and affected medications.

For a broader view, the SNP Lookup tool lets you search any rsID to see trait associations and clinical annotations. Developers can access the full annotation catalog via the Genomics API.

Ready to explore your pharmacogenomic profile? Try the free Pharmacogenomics Checker or sign up for an API key to build PGx features into your own applications.

Frequently Asked Questions

What is pharmacogenomics?

Pharmacogenomics is the study of how your genes affect your response to medications. Genetic variants in drug-metabolizing enzymes, transporters, and drug targets can determine whether a medication works well for you, has no effect, or causes adverse reactions. It is sometimes abbreviated as PGx.

Which genes are most important in pharmacogenomics?

The CYP enzyme family is the most clinically relevant. CYP2D6 metabolizes about 25% of all prescribed drugs, CYP2C19 handles clopidogrel and some antidepressants, CYP2C9 affects warfarin dosing, and CYP3A4 processes roughly half of all medications. Non-CYP genes like VKORC1, DPYD, TPMT, and SLCO1B1 also have strong clinical evidence.

What are metabolizer phenotypes?

Based on your genotype, you are classified into a metabolizer phenotype: poor metabolizer (PM) with very low enzyme activity, intermediate metabolizer (IM) with reduced activity, normal metabolizer (NM) with typical activity, or rapid/ultra-rapid metabolizer (RM/UM) with increased activity. These phenotypes predict how fast your body processes certain drugs.

Can 23andMe data be used for pharmacogenomics?

Yes, 23andMe raw data contains many pharmacogenomics-relevant SNPs. However, it does not cover all star alleles for every gene, and clinical-grade PGx testing from providers like GeneSight or OneOme is more comprehensive. DTC data is a useful starting point but should not replace clinical pharmacogenomic testing for medical decisions.

Should I change my medications based on pharmacogenomic results?

Never change medications without consulting your doctor or pharmacist. Pharmacogenomic results provide useful context, but dosing decisions must account for other factors like kidney function, drug interactions, age, and clinical history. Share your results with your healthcare provider and ask about Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines.

Try this yourself

500 free credits. No credit card required.